文献速递临床试验与 GCP流行病学与生物统计

延缓糖尿病进展试验(TRIPOD)随机对照试验的方案更新与基线特征

Protocol update and baseline characteristics for the TRIal to slow the Progression of Diabetes (TRIPOD) randomized controlled trial.
PubMed 文献 · Trials · 2023-11-14

TRIPOD随机对照试验旨在评估在常规照护基础上加入糖尿病管理包(DMP)能否改善2型糖尿病患者第6和第12个月的平均HbA1c水平。因招募困难,方案更新将分组比例从1:1:1改为10:1:10,样本量从339降至269,干预期从两年改为一年,主要假设仅关注常规照护组与DMP+M-POWER奖励组之间的差异。招募于2019年10月19日开始,2022年6月4日结束,基线平均年龄55.0岁(SD 9.7),64.2%为男性,平均基线HbA1c为8.10%(SD 0.95)。

要点

  • 方案更新后分组比例为10:1:10,样本量269,干预期一年。
  • 主要假设仅比较常规照护组与DMP+M-POWER奖励组。
  • 基线平均HbA1c为8.10%(SD 0.95),平均BMI为26.8 kg/m2(SD 5.3)。

核心结论

  • 所有预先计划的分析将进行并报告最终结果。

研究设计与样本

  • TRIPOD是一项随机对照试验,旨在确定在常规照护基础上加入基于证据的糖尿病管理包(DMP)能否改善2型糖尿病患者第6和第12个月的平均HbA1c水平。
  • 方案更新将分组比例从1:1:1(第1组-常规照护:第2组-DMP:第3组-DMP+M-POWER奖励)改为10:1:10,样本量从339改为269,干预期从两年改为一年,主要假设仅关注常规照护组与DMP+M-POWER奖励组之间的差异。
  • 招募于2019年10月19日开始,2022年6月4日结束;最终参与者于2023年6月8日完成第12个月随访数据收集。

主要发现

  • 参与者平均年龄为55.0岁(SD 9.7),64.2%为男性。
  • 76.8%的参与者为华裔,4.9%为马来裔,18.3%为印度裔及其他族裔。
  • 67.0%的参与者家庭月收入为4000新加坡元或以上。
  • 平均基线HbA1c为8.10%(SD 0.95),平均体重指数为26.8 kg/m2(SD 5.3)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes (T2D), a major risk factor for cardiovascular disease and other adverse health conditions, is on the rise in Singapore. TRIPOD is a randomized controlled trial aimed to determine whether complementing usual care with an evidence-based diabetes management package (DMP) -comprising access to an evidence-based app, health coaching, pedometer, glucometer and weighing scale, with or without a financial rewards scheme (M-POWER rewards), can improve mean HbA1c levels at months 6 and 12. METHODS: The protocol was published in Trials, accessible via https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3749-x 1. This manuscript updates the protocol with changes to the study design due to challenges with recruitment and presents baseline characteristics. Key updates include changing the arm allocation ratio from 1:1:1 (Arm 1-Usual Care: Arm 2-DMP: Arm 3-DMP+M-POWER rewards) to 10:1:10, the sample size from 339 to 269, the intervention period from two to one year, and the primary hypothesis to focus solely on differences between Usual Care and DMP+M-POWER rewards. Recruitment for the study began on 19 October 2019 and ended on 4 June 2022. RESULTS: The average age of participants was 55.0 (SD9.7) years old and 64.2% were male. The majority of participants (76.8%) were Chinese, 4.9% Malay and 18.3% Indian and of other ethnicities. 67.0% had a monthly household income of SGD$4000 or more. The mean baseline HbA1c was 8.10% (SD 0.95) and the mean body mass index was 26.8 kg/m2 (SD 5.3). DISCUSSION: The final participant completed month 12 follow-up data collection on 8 June 2023. All pre-planned analyses will be conducted and final results reported. TRIAL REGISTRATION: ClinicalTrials.gov NCT03800680 . Registered on 11 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bairavi J, Gardner DS, Yeoh E, et al. Protocol update and baseline characteristics for the TRIal to slow the Progression of Diabetes (TRIPOD) randomized controlled trial. Trials. 2023. PMID: 37964330. doi:10.1186/s13063-023-07770-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。